Akums Drugs and Pharmaceuticals Valuation

Is AKUMS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AKUMS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AKUMS (₹609.65) is trading below our estimate of fair value (₹770.44)

Significantly Below Fair Value: AKUMS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AKUMS?

Key metric: As AKUMS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AKUMS. This is calculated by dividing AKUMS's market cap by their current earnings.
What is AKUMS's PE Ratio?
PE Ratio	34.5x
Earnings	₹2.78b
Market Cap	₹91.39b

AKUMS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.2x
Enterprise Value/EBITDA	20.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does AKUMS's PE Ratio compare to its peers?

The above table shows the PE ratio for AKUMS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	47.5x
INNOVACAP Innova Captab	46.8x	29.7%	₹53.3b
INDGN Indegene	41.1x	18.4%	₹152.0b
SYNGENE Syngene International	70.5x	19.3%	₹341.4b
WINDLAS Windlas Biotech	31.6x	n/a	₹20.0b
AKUMS Akums Drugs and Pharmaceuticals	34.5x	n/a	₹91.4b

Price-To-Earnings vs Peers: AKUMS is good value based on its Price-To-Earnings Ratio (34.5x) compared to the peer average (47.5x).

Price to Earnings Ratio vs Industry

How does AKUMS's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: AKUMS is expensive based on its Price-To-Earnings Ratio (34.5x) compared to the Asian Life Sciences industry average (30.7x).

Price to Earnings Ratio vs Fair Ratio

What is AKUMS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AKUMS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	34.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AKUMS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Caplin Point Laboratories

₹148.3b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,952.15

-0.09%

60.0%

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹130.88

14.0%

21.4%

Vilin Bio Med

₹313.9m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹22.50

-4.9%

6.1%